PharmVar GeneFocus: CYP2D6
Clinical Pharmacology & Therapeutics2019Vol. 107(1), pp. 154–170
Citations Over TimeTop 1% of 2019 papers
Charity Nofziger, Amy Turner, Katrin Sangkuhl, Michelle Whirl‐Carrillo, José A. G. Agúndez, John L. Black, Henry M. Dunnenberger, Gualberto Ruaño, Martin A. Kennedy, Michael Phillips, Houda Hachad, Teri E. Klein, Andrea Gaedigk
Abstract
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism of numerous drugs and, thus, can impact drug efficacy and safety. This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Related Papers
- → Advances in Pharmacogenetics and Pharmacogenomics(2000)70 cited
- → Pharmacogenetics and pharmacogenomics as tools in cancer therapy(2016)32 cited
- → Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response(2015)1 cited
- [Pharmacogenomics: way to individual therapy].(2005)
- → Pharmacogenetics and Genetic Factors in Drug Dose-Response Relationships(2023)